Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.
about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsPotential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastomaAdvanced MR imaging of gliomas: an updateDiffusion-weighted MRI as a biomarker for treatment response in gliomaDiffusion-weighted MRI in neuro-oncology.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Diffusion MRI in early cancer therapeutic response assessment.Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumabPhysiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures.Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Bevacizumab in glioblastoma multiforme.Bevacizumab in high-grade gliomas: past, present, and future.The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network.Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC?Bevacizumab: radiation combination produces restricted diffusion on brain MRI.Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms.Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.
P2860
Q26853308-772B391B-F8EB-4D5B-992E-91AB116B23C2Q30652283-887CECFB-8004-4AB7-96A1-632A8C9BE034Q30655700-EC70B832-6766-47EC-8A55-31BCD19DB942Q30660991-9A6E181F-A76D-4BF9-B80F-F7DEFE120AE8Q30838362-DAC00F62-20E2-4B13-A531-AD46B74448DBQ30847284-5DFD40F0-60B0-474A-8B5E-B7426D6C280CQ31037179-AFC0A2A3-A317-479B-BD2A-C411316B4A5CQ34511741-F19C95E0-F85F-4A85-84FB-1BD257756A96Q35028897-F34C1F66-EF96-441C-A5EA-0A958FAE5362Q35771783-4AE5525A-F89B-4B30-AE13-9EDA9A8B1FF8Q35895174-FC1C4F42-C249-4FFC-867B-FD3E418FDB13Q36164058-FABB3D38-E5E3-4D0F-B19C-890FBCF66186Q36427409-788D4FFD-EFEC-4449-ADF3-6D21E9487D09Q36427538-89101D18-4A69-4C07-8420-ED5FCBE37490Q36785131-AA71899B-CFC3-430B-8BBC-F67777296DC4Q37510450-6AAADD0B-4BAB-44C6-81C9-8769AC7433D1Q37965628-79D31EFE-E1A0-4217-8712-505495DD5D0DQ38386873-1AEA5167-76DB-45F6-ABD7-2260FAEF01CFQ38904605-C3440933-0F35-4729-93CD-77187EF1D9BDQ39030177-7978C155-FB91-43F7-B810-73911B7B1EE1Q44500841-69545DD9-7D41-4191-BE21-3329DDA67159Q46524386-49601228-D42B-49FD-B203-AB57D536C478Q48318254-260CB474-2393-4A39-ACFB-F946272A1CE6Q48318624-C6B91C6E-2650-4D75-B88B-CA8164873BD7Q48330252-024978D5-FE70-4873-93AE-08BBE2C32760Q48468668-0D121F2A-0C18-425C-8E07-EC0E69A48A81Q48941681-D83DF8E4-1648-4121-8325-B576B667C1D6Q49499240-EFAF7E56-BE66-4628-946B-5245C0282327Q52562075-9E7B9917-BB91-4064-8A83-4414FA1A8C48Q55035317-0AA42FA4-FFC5-4006-88C3-BEF3DF2C44E0
P2860
Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Isolated diffusion restriction ...... of patients with glioblastoma.
@ast
Isolated diffusion restriction ...... of patients with glioblastoma.
@en
type
label
Isolated diffusion restriction ...... of patients with glioblastoma.
@ast
Isolated diffusion restriction ...... of patients with glioblastoma.
@en
prefLabel
Isolated diffusion restriction ...... of patients with glioblastoma.
@ast
Isolated diffusion restriction ...... of patients with glioblastoma.
@en
P2093
P2860
P356
P1476
Isolated diffusion restriction ...... of patients with glioblastoma.
@en
P2093
A B Lassman
A I Holodny
P2860
P304
P356
10.3174/AJNR.A2479
P50
P577
2011-05-19T00:00:00Z